Literature DB >> 31622861

The modulatory role of dopamine receptors in brain neuroinflammation.

Qing-Peng Xia1, Zhao-Yan Cheng1, Ling He2.   

Abstract

Neuroinflammation is a general pathological feature of central nervous system (CNS) diseases, primarily caused by activation of astrocytes and microglia, as well as the infiltration of peripheral immune cells. Inhibition of neuroinflammation is an important strategy in the treatment of brain disorders. Dopamine (DA) receptor, a significant G protein-coupled receptor (GPCR), is classified into two families: D1-like (D1 and D5) and D2-like (D2, D3 and D4) receptor families, according to their downstream signaling pathways. Traditionally, DA receptor forms a wide variety of psychological activities and motor functions, such as voluntary movement, working memory and learning. Recently, the role of DA receptor in neuroinflammation has been investigated widely, mainly focusing on nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome, renin-angiotensin system, αB-crystallin, as well as invading peripheral immune cells, including T cells, dendritic cells, macrophages and monocytes. This review briefly outlined the functions and signaling pathways of DA receptor subtypes as well as its role in inflammation-related glial cells, and subsequently summarized the mechanisms of DA receptors affecting neuroinflammation. Meaningfully, this article provided a theoretical basis for drug development targeting DA receptors in inflammation-related brain diseases.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dopamine receptor; Glial cell; NLRP3 inflammasome; Neuroinflammation; Peripheral immune cells; Renin-angiotensin system

Mesh:

Substances:

Year:  2019        PMID: 31622861     DOI: 10.1016/j.intimp.2019.105908

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

1.  Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway.

Authors:  Baoyu Shen; Dongxian Zhang; Xiaofeng Zeng; Lina Guan; Genmeng Yang; Liu Liu; Jian Huang; Yuanyuan Li; Shijun Hong; Lihua Li
Journal:  Psychopharmacology (Berl)       Date:  2022-01-08       Impact factor: 4.530

2.  Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease.

Authors:  Rowan Saloner; Mariana Cherner; David J Grelotti; Emily W Paolillo; David J Moore; Robert K Heaton; Scott L Letendre; Adarsh Kumar; Igor Grant; Ronald J Ellis
Journal:  Brain Behav Immun       Date:  2020-09-20       Impact factor: 7.217

Review 3.  Toward a better understanding of inflammatory microvesicles in alcohol use disorder.

Authors:  Ursula S Sandau; Jennifer M Loftis
Journal:  J Neurosci Res       Date:  2021-07-22       Impact factor: 4.433

4.  Early Adolescence Prefrontal Cortex Alterations in Female Rats Lacking Dopamine Transporter.

Authors:  Placido Illiano; Damiana Leo; Raul R Gainetdinov; Marta Pardo
Journal:  Biomedicines       Date:  2021-02-05

5.  Prefrontal dopamine D1 receptor manipulation influences anxiety behavior and induces neuroinflammation within the hippocampus.

Authors:  Dominik K E Beyer; Annika Mattukat; Nadja Freund
Journal:  Int J Bipolar Disord       Date:  2021-03-08

6.  Continuous Activation of Dopamine Receptors Alleviates LPS-Induced Liver Injury in Mice via β-arrestin2 Dependent Akt/NF-κB Pathway.

Authors:  Mingan Li; Ce Zhang; Lin Zhou; Xiaohui Sun; Tian Wang; Fenghua Fu
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810

7.  Forsythoside A Mitigates Alzheimer's-like Pathology by Inhibiting Ferroptosis-mediated Neuroinflammation via Nrf2/GPX4 Axis Activation.

Authors:  Chunyue Wang; Shanshan Chen; Hangyu Guo; Hongbo Jiang; Honghan Liu; Haoran Fu; Di Wang
Journal:  Int J Biol Sci       Date:  2022-02-28       Impact factor: 6.580

8.  Neuroinflammation in a Rat Model of Tourette Syndrome.

Authors:  Ke Zhongling; Chen Yanhui; Chen Guofeng; Liu Yanyan
Journal:  Front Behav Neurosci       Date:  2022-03-10       Impact factor: 3.558

9.  Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?

Authors:  Mikhail Melnikov; Mikhail Pashenkov; Alexey Boyko
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

10.  Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells.

Authors:  Sarah Thomas Broome; Teagan Fisher; Alen Faiz; Kevin A Keay; Giuseppe Musumeci; Ghaith Al-Badri; Alessandro Castorina
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.